Page 270 - Read Online

Feun. Hepatoma Res 2019;5:26 I http://dx.doi.org/10.20517/2394-5079.2019.19 Page 3 of 3

REFERENCES
1. Spieler B, Mellon EA, Jones PD, Giap H, et al. Stereotactic ablative radiotherapy for hepatocellular carcinoma. Hepatoma Res 2019;5:4.
2. Stereotactic body (SBRT) followedy by immunotherapy in liver cancer. NCT 03203304. Clinicaltrials. gov
3. Mehta A, Venkat SR, Portelance L, Feun LG. Congenital absence of the portal vein complicated by hepatocellular carcinoma in the
liver of an adult woman: review of imaging, literature and management. Hepatoma Res 2018;4:7.
4. Ayoub WS, Dailey F, Martin P, Jones PD. The impact of nucleos(t)ide analog therapy in hepatitis B on the incidence of hepatocellular
carcinoma: an update including recent literature findings. Hepatoma Res 2017;3:302-8.
5. Feun LG, Li YY, Wangpaichitr M, Wu CJ, Savaraj N. Immunotherapy for hepatocellular carcinoma: the force awakens in HCC?
Hepatoma Res 2017;3:43-51.
6. Kaseb A, Pestana RC, Vence LM, Blando JM, Singh S, et al. Randomized, open-label, perioperative phase II study evaluating
nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC. J Clin Oncol 2019;37:abstr4098